Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February
This article was originally published in The Gray Sheet
Executive Summary
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
You may also be interested in...
Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis
Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study
Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis
Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study
Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities
Johnson & Johnson/Cordis' inability to provide timely failure analysis reports of Cypher-related thrombosis complaints is one of several GMP violations cited in an April 1 FDA 1warning letter